Company Liminal BioSciences Inc. Toronto S.E.
Equities
LMNL
CA53272L1031
Biotechnology & Medical Research
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 51 | 08-07-13 | |
Director of Finance/CFO | 51 | 22-03-01 | |
Patrick Sartore
PSD | President | 49 | 05-12-31 |
Gary Bridger
CTO | Chief Tech/Sci/R&D Officer | 61 | 19-04-30 |
Director/Board Member | 67 | 14-05-13 | |
Shrinal Inamdar
IRC | Investor Relations Contact | - | - |
Marie Iskra
LAW | General Counsel | 48 | 19-08-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Gary Bridger
CTO | Chief Tech/Sci/R&D Officer | 61 | 19-04-30 |
Director/Board Member | 67 | 14-05-13 | |
Alek Krstajic
CHM | Chairman | 60 | 20-08-31 |
Neil Klompas
BRD | Director/Board Member | 52 | 19-04-30 |
Eugene Siklos
BRD | Director/Board Member | 60 | 20-08-31 |
Director/Board Member | 63 | 19-04-30 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 3,249,534 | 1,258,903 ( 38.74 %) | 0 | 38.74 % |
Company contact information
Liminal BioSciences, Inc.
440, boulevard Armand-Frappier Suite 300
H7V 4B4, Laval
+450 781 0115
http://www.liminalbiosciences.comSector
1st Jan change | Capi. | |
---|---|---|
+0.83% | 43.84B | |
+6.22% | 41.68B | |
+45.26% | 41.25B | |
-11.96% | 27.04B | |
+6.14% | 25.53B | |
-24.32% | 18.18B | |
-3.52% | 12.29B | |
+26.15% | 12.29B | |
+6.90% | 11.15B |